Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

New horizons for uncommon mutations in non-small cell lung cancer: BRAF, KRAS, RET, MET, NTRK, HER2

22 Apr 2022

Abstract excerpt

all with frequencies greater than 1%. Lung cancers harbouring these genome changes can potentially be treated with agents approved for other indications or under clinical development. This review updates the therapeutic arsenal that especially targets those genes.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to Colorectal Cancer Treatments and Studies
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35582653
DOI: 10.5306/wjco.v13.i4.276

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

New horizons for uncommon mutations in non-small cell lung cancer: BRAF, KRAS, RET, MET, NTRK, HER2PMID 35582653Read ↗

KRAS and MET in non-small-cell lung cancer: two of the new kids on the 'drivers' block.Semantic proximity Read ↗

Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma.Semantic proximity Read ↗

Molecular Epidemiology of the Main Druggable Genetic Alterations in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Targeting molecular alterations in non-small-cell lung cancer: what's next?Semantic proximity Read ↗

Targeted Therapy for Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Novel therapeutic strategies for rare mutations in non-small cell lung cancer.Semantic proximity Read ↗

Treatment of Patients With Non-Small-Cell Lung Cancer Harboring Rare Oncogenic Mutations.Semantic proximity Read ↗

Molecular therapeutic targets in non-small cell lung cancer.Semantic proximity Read ↗

Rare molecular subtypes of lung cancer.Semantic proximity Read ↗

Targeting Infrequent Driver Alterations in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusionSemantic proximity Read ↗

New Targets in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.